Table 2.

The baseline characteristics of the participants by intervention, placebo groups and overall

Baseline characteristic	Intervention (GKT137831) group (n = xxx)		Placebo group (n = xxx)		Percentage standardised difference	Overall (n = xxx)
	Values	Missing, n (%)	Values	Missing, n (%)		Values	Missing, n (%)
Urine albumin–creatinine ratio (UACR) (log-transformed)
Mean (standard deviation (SD))
Estimated glomerular filtration rate (eGFR) (log-transformed)
Mean (SD)
Gender
Male, n (%)
Female, n (%)
Age (years),
Mean (SD)
Ethnicity
xx, n (%)
Other, n (%)
Clinical variables
Systolic blood pressure (mmHg), mean (SD)
Diastolic blood pressure (mmHg), mean (SD)
Use of angiotensin-converting-enzyme inhibitor (ACEi), n (%)
Use of angiotensin II receptor blocker (ARB), n (%)
Body mass index (kg/m2), mean (SD)
Duration of diabetes mellitus at baseline (years), mean (SD)
Glycated haemoglobin (HbA1c %), median (25th–75th percentile)